Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The minor gentamicin complex component, X2, is a potent premature stop codon readthrough molecule with therapeutic potential.
Friesen WJ, Johnson B, Sierra J, Zhuo J, Vazirani P, Xue X, Tomizawa Y, Baiazitov R, Morrill C, Ren H, Babu S, Moon YC, Branstrom A, Mollin A, Hedrick J, Sheedy J, Elfring G, Weetall M, Colacino JM, Welch EM, Peltz SW. Friesen WJ, et al. Among authors: sierra j. PLoS One. 2018 Oct 25;13(10):e0206158. doi: 10.1371/journal.pone.0206158. eCollection 2018. PLoS One. 2018. PMID: 30359426 Free PMC article.
The nucleoside analog clitocine is a potent and efficacious readthrough agent.
Friesen WJ, Trotta CR, Tomizawa Y, Zhuo J, Johnson B, Sierra J, Roy B, Weetall M, Hedrick J, Sheedy J, Takasugi J, Moon YC, Babu S, Baiazitov R, Leszyk JD, Davis TW, Colacino JM, Peltz SW, Welch EM. Friesen WJ, et al. Among authors: sierra j. RNA. 2017 Apr;23(4):567-577. doi: 10.1261/rna.060236.116. Epub 2017 Jan 17. RNA. 2017. PMID: 28096517 Free PMC article.
Guanidino quinazolines and pyrimidines promote readthrough of premature termination codons in cells with native nonsense mutations.
Morrill C, Friesen WJ, Babu S, Baiazitov RY, Du W, Karloff DB, Lee CS, Moon YC, Ren H, Sierra J, Tomizawa Y, Vazirani P, Welch EM, Xue X, Zhuo J. Morrill C, et al. Among authors: sierra j. Bioorg Med Chem Lett. 2022 Nov 15;76:128989. doi: 10.1016/j.bmcl.2022.128989. Epub 2022 Sep 20. Bioorg Med Chem Lett. 2022. PMID: 36150638
Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia.
Jiménez-Vicente C, Arribas I, Pomares H, Ramil G, Castaño-Diez S, Pérez-Valencia AI, Sturla AL, López-Guerra M, Martinez-Roca A, Zugasti I, Guijarro F, Cortés-Bullich A, Merchán B, Triguero A, Monge I, Tuca A, Oñate G, Garrido A, Sierra J, Arnan M, Esteve J, Díaz-Beyá M; Spanish CETLAM Group. Jiménez-Vicente C, et al. Among authors: sierra j. Haematologica. 2025 Jan 23. doi: 10.3324/haematol.2024.286589. Online ahead of print. Haematologica. 2025. PMID: 39844754 Free article.
HSP-CAR30 WITH A HIGH PROPORTION OF LESS-DIFFERENTIATED T CELLS PROMOTES DURABLE RESPONSES IN REFRACTORY CD30+ LYMPHOMA.
Caballero Gonzalez AC, Ujaldón-Miró C, Pujol-Fernández P, Montserrat-Torres R, Guardiola-Perello M, Escudero-López E, Garcia-Cadenas I, Esquirol A, Martino R, Jara-Bustamante P, Ezquerra Condeminas P, Soria JM, Iranzo Ribera E, Moreno-Martinez ME, Riba M, Sierra J, Alvarez-Fernández C, Escribà-Garcia L, Briones J. Caballero Gonzalez AC, et al. Among authors: sierra j. Blood. 2025 Jan 22:blood.2024026758. doi: 10.1182/blood.2024026758. Online ahead of print. Blood. 2025. PMID: 39841453
Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group.
Oñate G, Garrido A, Arnan M, Pomares H, Alonso E, Tormo M, Diaz-Beya M, Vives S, Zamora L, Sampol A, Coll R, Salamero O, Cervera M, Garcia A, Vall-Llovera F, Garcia-Avila S, Bargay J, Ortin X, Iranzo E, Guijarro F, Pratcorona M, Nomdedeu JF, Esteve J, Sierra J. Oñate G, et al. Among authors: sierra j. Blood Cancer J. 2025 Jan 11;15(1):4. doi: 10.1038/s41408-024-01205-5. Blood Cancer J. 2025. PMID: 39799145 Free PMC article.
1,169 results